RNA Drug Platforms

RNA 

platform

Multi-omics platform

Delivery

platform

Nucleotide modification platform

Druggability of RNA is determined by multiple aspects, resembling the barrel theory, in which defects in any aspects may interfere RNA druggability.  NeoCura builds 4 important platforms in the early stage and applied related patents to boost RNA druggability. The platforms include RNA platform (3 different RNA types), delivery platform (LNP delivery system and new delivery system), multi-omics platform (NGS, ribo-Seq, SHAPE-seq) and nucleotide modification platform. The 4 platforms are working together and keeping a balanced development to maximize RNA overall druggability.







Scan ¡°code¡± to follow us on WeChat

NeoCura Bio-Medical Technology Co., Ltd.

Beijing: 3/F, Building 1,20 Life Science Park Road, Life Science Park,Changping District, Beijing





Website£ºwww.neocura.com.cn

E-mail£ºinfo@neocura.net

             bd@neocura.net

             pr@neocura.net

Tel£º+86 10 80766127




Guangzhou: 10/F, Block B, No. 388 Lianyun Road, Huangpu District, Guangzhou, China





Shenzhen: 12/F, Block B, Building 1, Yinxingzhijie Phase II, Longhua District, Shenzhen, China

Address:

  • Telephone

    • 010-80766127
  • ΢ÐÅɨһɨ

seo seo